Abstract:

Objective
To explore the effect of rosiglitazone in the treatment of Alzheimer’s disease(AD) and provide guidance for AD treatment. Methods A thorough literature search related to randomized controlled trial(RCT) or clinical controlled trial(CCT) on treatment of AD with rosiglitazone was performed among Medline and database of CNKI in accordance with the requirements of Cochrane systematic review. Two reviewers reviewed the original articles,abstracted data and assigned an initial quality rating independently. With RevMan 5.0 software,Meta-analysis was carried out on the three literatures which were accorded with the criterion. Results Eight studies were included. All the studies reported and measured the changes in ADAS-cog score from baseline to endpoint for active treatment compared with placebo and there was a significant difference between two groups（WMD=－0.39，95%CI=－0.69－－0.08,P=0.01）. No significant difference of safety was detected between placebo and treatment groups（OR=1.16，95%CI＝0.97－1.37，P=0.10）. But a significant difference was observed when the data was stratified by dosage,the incidence of adverse events in patients who took 8 mg rosiglitazone everyday was roughly as 1.33 times as those who took placebo（OR95%CI＝1.13－1.56）. Conclusion Rosiglitazone can to some extent improve cognitive function of AD patients. However,the safety should be considered when it is applied.
 

Key words: rosiglitazone；Alzheimer’s disease；Meta-analysis